Top

Published in:

Open Access 01-07-2018 | Review

Systematic review of blood diagnostic markers in colorectal cancer

Authors: Stella Nikolaou, Shengyang Qiu, Francesca Fiorentino, Shahnawaz Rasheed, Paris Tekkis, Christos Kontovounisios

Published in: Techniques in Coloproctology | Issue 7/2018

Abstract

The purpose of this systematic review was to compare the diagnostic ability of blood markers for colorectal cancer (CRC). A systematic review of the literature for diagnostic blood markers for primary human colorectal cancer over the last 5 years was performed. The primary outcome was to assess the diagnostic ability of these markers in diagnosing colorectal cancer. The secondary outcome was to see whether the marker was compared to other markers. The tertiary outcome was to assess diagnostic ability in early versus late CRC, including stage IV disease. We identified 51 studies (29 prospective, 14 retrospective, and 8 meta-analyses). The markers were divided in broadly four groups: nucleic acids (RNA/DNA/messenger RNA/microRNAs), cytokines, antibodies, and proteins. The most promising circulating markers identified among the nucleid acids were NEAT_v2 non-coding RNA, SDC2 methylated DNA, and SEPT9 methylated DNA. The most promising cytokine to detect CRC was interleukin 8, and the most promising circulating proteins were CA11-19 glycoprotein and DC-SIGN/DC-SIGNR. Sensitivities of these markers for detecting primary colorectal carcinoma ranged from 70 to 98% and specificities from 84 to 98.7%. The best studied blood marker was SEPT9 methylated DNA, which showed great variability with sensitivities ranging from 48.2 to 95.6% and specificities from 80 to 98.9%, making its clinical applicability challenging. If combined with fecal immunochemical test (FIT), the sensitivity improved from 78 to 94% in detecting CRC. Methylated SEPT9, methylated SDC2, and -SIGN/DC-SIGNR protein had better sensitivity and specificity than CEA or CA 19-9. With the exception of SEPT9 which is currently being implemented as a screening test for CRC all other markers lacked reproducibility and standardization and were studied in relatively small population samples.

UK CR (2018) Bowel cancer mortality statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/mortality. Accessed 1 Apr 2018

Heiss JA, Brenner H (2017) Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting. Clin Epigenetics 9:24. https://doi.org/10.1186/s13148-017-0322-x CrossRefPubMedPubMedCentral

Toiyama Y, Tanaka K, Inoue Y, Mohri Y, Kusunoki M (2016) Circulating cell-free microRNAs as biomarkers for colorectal cancer. Surg Today 46(1):13–24. https://doi.org/10.1007/s00595-015-1138-y CrossRefPubMed

Lin J, Chuang C-C, Zuo L (2017) Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets. Oncotarget. https://doi.org/10.18632/oncotarget.14461 CrossRefPubMedPubMedCentral

Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, Byrne S, Bambacas L, Hollington P, Symonds EL (2016) A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med 5(10):2763–2772. https://doi.org/10.1002/cam4.868 CrossRefPubMedPubMedCentral

Vatandoost N, Ghanbari J, Mojaver M, Avan A, Ghayour-Mobarhan M, Nedaeinia R, Salehi R (2016) Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol 142(2):341–351. https://doi.org/10.1007/s00432-015-1928-z CrossRefPubMed

Brenner H, Stock C, Hoffmeister M (2015) Colorectal cancer screening: the time to act is now. BMC Med. https://doi.org/10.1186/s12916-015-0498-x CrossRefPubMedPubMedCentral

Lim DH, Lee JH, Kim JW (2017) Feasibility of CYFRA 21—1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45. J Clin Lab Anal. https://doi.org/10.1002/jcla.22163 PubMedCentralCrossRefPubMed

Werner S, Krause F, Rolny V, Strobl M, Morgenstern D, Datz C, Chen H, Brenner H (2016) Evaluation of a 5-marker blood test for colorectal cancer early detection in a colorectal cancer screening setting. Clin Cancer Res 22(7):1725–1733. https://doi.org/10.1158/1078-0432.ccr-15-1268 CrossRefPubMed

10.

New bowel cancer screening test (2016). https://www.gov.uk/government/news/new-bowel-cancer-screening-test. Accessed 13 Dec 2017

11.

Imaoka H, Toiyama Y, Fujikawa H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, Toden S, Goel A, Kusunoki M (2016) Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol 27(10):1879–1886. https://doi.org/10.1093/annonc/mdw279 CrossRefPubMed

12.

Zhang HH, Li PW, Ju HX, Pesta M, Kulda V, Jin WJ, Cai M, Liu CB, Wu H, Xu JM, Ye Y, Zhang GL, Xu EP, Cai JT, Lai MD, Xia DJ, Yang J, Wu YH (2014) Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis. Cancer Epidemiol Biomark Prev 23(12):2783–2792. https://doi.org/10.1158/1055-9965.epi-14-0598 CrossRef

13.

Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, Liang X, Su Y, Hu Q, Wang F, Zhang Z-Y (2015) Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res 34:86. https://doi.org/10.1186/s13046-015-0198-6 CrossRefPubMedPubMedCentral

14.

Nian J, Sun X, Ming S, Yan C, Ma Y, Feng Y, Yang L, Yu M, Zhang G, Wang X (2017) Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis. Clin Transl Gastroenterol 8(1):e216. https://doi.org/10.1038/ctg.2016.66 CrossRefPubMedPubMedCentral

15.

Wu YC, Yang L, Zhao J, Li C, Nie J, Liu FQ, Zhuo CH, Zheng YX, Li B, Wang ZM, Xu Y (2015) Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer. Mol Cancer. https://doi.org/10.1186/s12943-015-0455-5 CrossRefPubMedPubMedCentral

16.

Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY, Ju SQ (2014) Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer 111(8):1482–1489. https://doi.org/10.1038/bjc.2014.470 CrossRefPubMedPubMedCentral

17.

Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, Kim TS, Kim NK, Chung HC, An S (2013) Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn 15(4):498–507. https://doi.org/10.1016/j.jmoldx.2013.03.004 CrossRefPubMed

18.

Li W, Zhang G, Wang HL, Wang L (2016) Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease. Eur Rev Med Pharmacol Sci 20(23):4874–4879PubMed

19.

Khales SA, Abbaszadegan MR, Abdollahi A, Raeisossadati R, Tousi MF, Forghanifard MM (2015) SALL4 as a new biomarker for early colorectal cancers. Cancer Res Clin Oncol 141(2):229–235. https://doi.org/10.1007/s00432-014-1808-y CrossRef

20.

Xia WJ, Chen WZ, Zhang ZG, Wu D, Wu P, Chen ZG, Li C, Huang J (2015) Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis. PloS One. https://doi.org/10.1371/journal.pone.0123484 CrossRefPubMedPubMedCentral

21.

Li Q, Wang K, Su C, Fang J (2016) Serum trefoil factor 3 as a protein biomarker for the diagnosis of colorectal cancer. Technol Cancer Res Treat. https://doi.org/10.1177/1533034616674323 CrossRefPubMedPubMedCentral

22.

Overholt BF, Wheeler DJ, Jordan T, Fritsche HA (2016) CA11-19: a tumor marker for the detection of colorectal cancer. Gastrointest Endosc 83(3):545–551. https://doi.org/10.1016/j.gie.2015.06.041 CrossRefPubMed

23.

Fung KYC, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, Cosgrove LJ (2015) Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One. https://doi.org/10.1371/journal.pone.0120425 CrossRefPubMedPubMedCentral

24.

Jiang Y, Zhang C, Chen K, Chen Z, Sun Z, Zhang Z, Ding D, Ren S, Zuo Y (2014) The clinical significance of DC-SIGN and DC-SIGNR, which are novel markers expressed in human colon cancer. PLoS One 9(12):e114748. https://doi.org/10.1371/journal.pone.0114748 CrossRefPubMedPubMedCentral

25.

Jin WJ, Xu JM, Xu WL, Gu DH, Li PW (2014) Diagnostic value of interleukin-8 in colorectal cancer: a case–control study and meta-analysis. World J Gastroenterol 20(43):16334–16342. https://doi.org/10.3748/wjg.v20.i43.16334 CrossRefPubMedPubMedCentral

26.

Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N, He YQ, Han XL, Hang J, Zhang J, Song LL, Han Y, Sheng JQ (2015) Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 30(5):830–833. https://doi.org/10.1111/jgh.12855 CrossRefPubMed

27.

Heichman KA (2014) Blood-based testing for colorectal cancer screening. Mol Diagn Ther 18(2):127–135. https://doi.org/10.1007/s40291-013-0074-z CrossRefPubMed

28.

Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grutzmann R, Pilarsky C, Sledziewski A (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54(2):414–423. https://doi.org/10.1373/clinchem.2007.095992 CrossRefPubMed

29.

deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grutzmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55(7):1337–1346. https://doi.org/10.1373/clinchem.2008.115808 CrossRefPubMed

30.

Church T (2014) Colorectal cancer screening: will non-invasive procedures triumph? Genome Med. https://doi.org/10.1186/gm562 CrossRefPubMedPubMedCentral

31.

Fu B, Yan P, Zhang S, Lu Y, Pan L, Tang W, Chen S, Chen S, Zhang A, Liu W (2018) Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Mark 2018:6437104. https://doi.org/10.1155/2018/6437104 CrossRef

32.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ (2009) Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 101(20):1412–1422. https://doi.org/10.1093/jnci/djp319 CrossRefPubMedPubMedCentral

33.

Ladabaum U, Alvarez-Osorio L, Rösch T, Brueggenjuergen B (2014) Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. Endosc Int Open 2(2):E96–E104. https://doi.org/10.1055/s-0034-1377182 CrossRefPubMedPubMedCentral

34.

Li L, Guo Y, Chen Y, Wang J, Zhen L, Guo X, Liu J, Jing C (2016) The diagnostic efficacy and biological effects of microRNA-29b for colon cancer. Technol Cancer Res Treat 15(6):772–779CrossRefPubMed

35.

Basati G, Razavi AE, Pakzad I, Malayeri FA (2016) Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 37(2):1781–1788. https://doi.org/10.1007/s13277-015-3967-0 CrossRef

36.

Zhi ML, Liu ZJ, Yi XY, Zhang LJ, Bao YX (2015) Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. Genet Mol Res 14(4):18018–18025. https://doi.org/10.4238/2015.December.22.28 CrossRefPubMed

37.

Xu F, Xu L, Wang M, An G, Feng G (2015) The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 17(5):O100–O107. https://doi.org/10.1111/codi.12917 CrossRefPubMed

38.

Lv ZC, Fan YS, Chen HB, Zhao DW (2015) Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 36(3):1619–1625. https://doi.org/10.1007/s13277-014-2760-9 CrossRef

39.

Chen WY, Zhao XJ, Yu ZF, Hu FL, Liu YP, Cui BB, Dong XS, Zhao YS (2015) The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer. Int J Clin Exp Pathol 8(6):7092–7101PubMedPubMedCentral

40.

Zhang J, Zhang KJ, Bi MS, Jiao XL, Zhang DL, Dong Q (2014) Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anti Cancer Drugs 25(3):346–352. https://doi.org/10.1097/cad.0000000000000049 CrossRefPubMed

41.

Yang X, Zeng ZY, Hou YX, Yuan TX, Gao C, Jia W, Yi XY, Liu MR (2014) MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. https://doi.org/10.1371/journal.pone.0088745 CrossRefPubMedPubMedCentral

42.

Xu LL, Li MZ, Wang M, Yan D, Feng GS, An GY (2014) The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer. https://doi.org/10.1186/1471-2407-14-714 CrossRefPubMedPubMedCentral

43.

Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, Takemasa I, Mizushima T, Okuzaki D, Yamamoto H, Doki Y, Mori M (2014) Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep 32(6):2354–2358. https://doi.org/10.3892/or.2014.3515 CrossRefPubMed

44.

Zhu M, Huang Z, Zhu D, Zhou X, Shan X, Qi LW, Wu L, Cheng W, Zhu J, Zhang L, Zhang H, Chen Y, Zhu W, Wang T, Liu P (2017) A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget. https://doi.org/10.18632/oncotarget.15059 CrossRefPubMedPubMedCentral

45.

Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O (2016) Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis 37(10):941–950. https://doi.org/10.1093/carcin/bgw078 CrossRefPubMed

46.

Fang ZX, Tang J, Bai YY, Lin HY, You HY, Jin HW, Lin LQ, You P, Li J, Dai Z, Liang XM, Su YH, Hu Q, Wang F, Zhang ZY (2015) Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. https://doi.org/10.1186/s13046-015-0198-6 CrossRefPubMedPubMedCentral

47.

Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, Peng H, Che YQ, Huang CZ (2014) Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 9(4):e87451. https://doi.org/10.1371/journal.pone.0087451 CrossRefPubMedPubMedCentral

48.

Zhang GJ, Zhou T, Liu ZL, Tian HP, Xia SS (2013) Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. Mol Clin Oncol 1(2):379–384. https://doi.org/10.3892/mco.2013.61 CrossRefPubMedPubMedCentral

49.

Luo X, Stock C, Burwinkel B, Brenner H (2013) Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 8(5):e62880. https://doi.org/10.1371/journal.pone.0062880 CrossRefPubMedPubMedCentral

50.

Nagai Y, Sunami E, Yamamoto Y, Hata K, Okada S, Murono K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Ishihara S, Hoon DSB, Watanabe T (2017) LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.14439 CrossRefPubMedPubMedCentral

51.

Pedersen SK, Symonds EL, Baker RT, Murray DH, McEvoy A, Van Doorn SC, Mundt MW, Cole SR, Gopalsamy G, Mangira D, LaPointe LC, Dekker E, Young GP (2015) Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer 15:654. https://doi.org/10.1186/s12885-015-1674-2 CrossRefPubMedPubMedCentral

52.

Qi J, Qian C, Shi W, Wu XH, Jing RR, Zhang LR, Wang ZW, Ju SQ (2013) Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. Clin Biochem 46(1–2):64–69. https://doi.org/10.1016/j.clinbiochem.2012.08.026 CrossRefPubMed

53.

Rodia MT, Ugolini G, Mattei G, Montroni I, Zattoni D, Ghignone F, Veronese G, Marisi G, Lauriola M, Strippoli P, Solmi R (2016) Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget 7(21):30295–30306. https://doi.org/10.18632/oncotarget.8108 CrossRefPubMedPubMedCentral

54.

Wang X, Yang Z, Tian H, Li Y, Li M, Zhao W, Zhang C, Wang T, Liu J, Zhang A, Shen D, Zheng C, Qi J, Zhao D, Shi J, Jin L, Rao J, Zhang W (2017) Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.15279 CrossRefPubMedPubMedCentral

55.

Xu J, Ye Y, Zhang H, Szmitkowski M, Makinen MJ, Li P, Xia D, Yang J, Wu Y, Wu H (2016) Diagnostic and Prognostic value of serum interleukin-6 in colorectal cancer. Medicine 95(2):e2502. https://doi.org/10.1097/md.0000000000002502 CrossRefPubMedPubMedCentral

56.

Zheng ZX, Zheng M, Bi JJ, Feng Q, Yue ZG, Zhou YQ, Hu WN, Zhang HZ, Gao HJ (2015) Serum GRO beta: a potential tumor-associated biomarker for colorectal cancer. Int J Clin Exp Med 8(2):2526–2535PubMedPubMedCentral

57.

Kunizaki M, Sawai T, Takeshita H, Tominaga T, Hidaka S, To K, Miyazaki T, Hamamoto R, Nanashima A, Nagayasu T (2016) Clinical value of serum p53 antibody in the diagnosis and prognosis of colorectal cancer. Anticancer Res 36(8):4171–4175PubMed

58.

Chen H, Werner S, Butt J, Zornig I, Knebel P, Michel A, Eichmuller SB, Jager D, Waterboer T, Pawlita M, Brenner H (2016) Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget 7(13):16420–16432. https://doi.org/10.18632/oncotarget.7500 PubMedPubMedCentralCrossRef

59.

Wang HF, Li LF, Guo SH, Zeng QY, Ning F, Liu WL, Zhang G (2016) Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep 6:33440. https://doi.org/10.1038/srep33440 CrossRefPubMedPubMedCentral

60.

Fei W, Chen L, Chen J, Shi Q, Zhang L, Liu S, Li L, Zheng L, Hu X (2017) RBP4 and THBS2 are serum biomarkers for diagnosis of colorectal cancer. Oncotarget 8(54):92254–92264. https://doi.org/10.18632/oncotarget.21173 CrossRefPubMedPubMedCentral

61.

Wang X-Q, Tang Z-X, Yu D, Cui S-J, Jiang Y-H, Zhang Q, Wang J, Yang P-Y, Liu F (2016) Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma. Oncotarget 7(8):8823–8838. https://doi.org/10.18632/oncotarget.6815 PubMedPubMedCentralCrossRef

62.

Gezer U, Yoruker EE, Keskin M, Kulle CB, Dharuman Y, Holdenrieder S (2015) Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci 16(12):29654–29662. https://doi.org/10.3390/ijms161226180 CrossRefPubMedPubMedCentral

63.

Xue YM, Yu FD, Yan DW, Cui FF, Tang HM, Wang XL, Chen J, Lu HJ, Zhao SL, Peng ZH (2015) Zinc-alpha-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population. Int J Mol Sci 16(1):691–703. https://doi.org/10.3390/ijms16010691 CrossRef

64.

Wang ZQ, Sun XL, Su HL, Liu XF, Xuan YJ, Yu SQ (2015) Association between serum angiopoietin-2 concentration and clinicopathological parameters in patients with colorectal cancer. Genet Mol Res 14(4):15547–15552. https://doi.org/10.4238/2015.December.1.5 CrossRefPubMed

65.

Storm L, Christensen IJ, Jensenius JC, Nielsen HJ, Thiel S, Danish Study Grp Early D (2015) Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunol Immunother 64(1):41–50. https://doi.org/10.1007/s00262-014-1615-y CrossRefPubMed

66.

Fung KY, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, Cosgrove LJ (2015) Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One 10(3):e0120425. https://doi.org/10.1371/journal.pone.0120425 CrossRefPubMedPubMedCentral

67.

Sole X, Crous-Bou M, Cordero D, Olivares D, Guino E, Sanz-Pamplona R, Rodriguez-Moranta F, Sanjuan X, de Oca J, Salazar R, Moreno V (2014) Discovery and validation of new potential biomarkers for early detection of colon cancer. PLoS One 9(9):e106748. https://doi.org/10.1371/journal.pone.0106748 CrossRefPubMedPubMedCentral

68.

Shin J, Kim HJ, Kim G, Song M, Woo SJ, Lee ST, Kim H, Lee C (2014) Discovery of melanotransferrin as a serological marker of colorectal cancer by secretome analysis and quantitative proteomics. J Proteome Res 13(11):4919–4931. https://doi.org/10.1021/pr500790f CrossRefPubMed

69.

Shirahata A, Hibi K (2014) Serum vimentin methylation as a potential marker for colorectal cancer. Anticancer Res 34(8):4121–4125PubMed

70.

Wang J, Wang X, Lin S, Chen C, Wang C, Ma Q, Jiang B (2013) Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 8(7):e70519. https://doi.org/10.1371/journal.pone.0070519 CrossRefPubMedPubMedCentral

Title: Systematic review of blood diagnostic markers in colorectal cancer
Authors: Stella Nikolaou
Shengyang Qiu
Francesca Fiorentino
Shahnawaz Rasheed
Paris Tekkis
Christos Kontovounisios
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: Techniques in Coloproctology / Issue 7/2018
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI: https://doi.org/10.1007/s10151-018-1820-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Systematic review of blood diagnostic markers in colorectal cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2018

Rectal perforation after Doppler-guided hemorrhoidal dearterialization treated with diverting sigmoidostomy

Robotic transanal minimally invasive surgery (TAMIS) for local excision of rectal lesions with the da Vinci Xi (dVXi): technical considerations and video vignette

Is it correct to perform omentoplasty to repair rectovaginal fistulas in oncological patients?

Authors reply: Damage control surgery in patients with generalized peritonitis secondary to perforated diverticulitis—the risk of overtreatment

Clinical value of pouchogram prior to ileostomy closure after ileal pouch anal anastomosis

Mediterranean Society of Coloproctology meeting report